# Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.

> **NCT05375097** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 162 (actual)

## Conditions studied

- Migraine

## Interventions

- **OTHER:** Erenumab

## Key facts

- **NCT ID:** NCT05375097
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-03
- **Primary completion:** 2021-05-14
- **Final completion:** 2021-05-14
- **Target enrollment:** 162 (ACTUAL)
- **Last updated:** 2022-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05375097

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05375097, "Real-world Impact of Erenumab on Sick-leaves, Health Care Resource Use and Comorbidities.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05375097. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*